Efficacy and tolerance of Beta Blocker and Procoralan uptitration in chronic heart failure patients under telemedical control: „70 bpm on day 28 - EARLY

German Foundation for Chronically Ill0 个研究点开始时间: 2014年6月23日最近更新: 2015年1月19日

适应症

试验速览

暂无简介。

•Symptomatic heart failure with reduced left ventricular function caused by dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICMP)
•Heart rate = 75 bpm
•NYHA Class II-IV
•Sinus rhythm
•Cognitive capacity
•Age = 18 years
•Stable HF medication including beta-blocker
•Dose of beta-blocker = 50% of advised dose according to German product information or beta-blocker naive patient
•Signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 70
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

•Systolic blood pressure < 95 mm Hg
•Cardiac decompensation within the last 8 weeks prior to recruitment
•Significantly reduced renal function (GFR < 30)
•Planned invasive medical intervention within the next 8 weeks
•Lack of communication skills
•Permanent atrial fibrillation and/or paroxysmal AF documented in two ECGs
•Implanted active CRT-Device or active pacemaker
•Patients with a contraindication for beta-blocker therapy
•Patients under current Ivabradine-therapy
•Patients paticipats in a competing clinical trial (identical/overlapping) inclusion criteria
•Patients living in a geographic region without sufficient cell network coverage

发起方

German Foundation for Chronically Ill